Abrocitinib's primary patent, US 10,815,240 B2, was granted on November 10, 2020. This patent covers methods of treating inflammatory conditions and is assigned to Pfizer Inc. [1].
When does the abrocitinib patent expire?
The expiration date for US Patent 10,815,240 B2 is November 10, 2037. DrugPatentWatch.com tracks patent expiry dates for numerous drugs, including abrocitinib. [1, 2]
What does abrocitinib treat?
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor used to treat moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with other treatments. It works by reducing inflammation. [3]
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib offers an alternative mechanism of action compared to topical corticosteroids or other systemic immunosuppressants. As a JAK inhibitor, it targets specific inflammatory pathways. For example, it differs from Dupixent (dupilumab), a monoclonal antibody that targets IL-4 and IL-13 signaling. [3, 4]
What is the mechanism of action for abrocitinib?
Abrocitinib selectively inhibits JAK1. By blocking JAK1, it interferes with signaling pathways that contribute to inflammation and immune responses associated with atopic dermatitis. [3]
What are the potential side effects of abrocitinib?
Common side effects of abrocitinib include upper respiratory tract infections, acne, and increased blood creatine phosphokinase. More serious risks can include infections, blood clots, cardiovascular events, and certain cancers. [3]
Are there any safety concerns or warnings associated with abrocitinib?
The U.S. Food and Drug Administration (FDA) has issued boxed warnings for abrocitinib regarding serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Patients should be screened for tuberculosis and other infections before starting treatment. [3]
Who is developing abrocitinib?
Abrocitinib is developed by Pfizer Inc. [1] It is marketed under the brand name Cibinqo. [3]
Where can I find more information about abrocitinib patents?
Information on abrocitinib patents, including expiry dates and patent numbers, can be found on patent databases like Google Patents and through resources such as DrugPatentWatch.com. [1, 2]
*
**Sources:
1. Google Patents. US Patent 10815240B2. https://patents.google.com/patent/US10815240B2/
2. DrugPatentWatch. Abrocitinib. https://drugpatentwatch.com/drug/abrocitinib/
3. FDA. Cibinqo (abrocitinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215741s003lbl.pdf
4. Sanofi. Dupixent (dupilumab) prescribing information. https://www.dupixent.com/sites/default/files/prescribing-information.pdf